ASAS既定定义与数据驱动初步临界值对nr-axSpA试验入组资格的比较
本研究为COAST-X试验的事后分析,比较2009年ASAS既定定义与2021年初步数据驱动定义在筛选非放射学中轴型脊柱关节炎(nr-axSpA)临床试验入组患者时的表现。结果显示,符合两种定义的患者在基线特征和第16周临床结局上相似,且数据驱动定义并未优于既定定义。
要点
- 符合既定定义或数据驱动定义的患者基线特征与第16周临床结局相似。
- 仅符合既定定义或仅符合数据驱动定义的亚组结局略低。
- 数据驱动定义在筛选nr-axSpA试验患者方面未优于既定定义。
核心结论
- 符合既定定义或数据驱动定义的nr-axSpA患者基线特征和第16周临床结局相似,数据驱动定义未优于既定定义。
研究设计与样本
- COAST-X研究的事后分析,基于3期多中心随机双盲安慰剂对照试验中ixekizumab或安慰剂治疗至52周的nr-axSpA患者。
主要发现
- 各既定定义或数据驱动定义阳性亚组间患者 demographics 和基线疾病特征均衡。
- 各治疗臂内,不同定义阳性亚组的第16周临床结局相似。
- 仅符合既定定义或仅符合数据驱动定义的亚组结局略低于任一阳性亚组。
关键数值与推荐
- 既定定义基于MRI骶髂关节骨髓水肿(BME);数据驱动定义包括PD-BME、PD-侵蚀/脂肪病变/深部脂肪病变及PD Total临界值。
临床怎么用
- 在nr-axSpA临床试验入组中,数据驱动定义未显示出优于既定定义的筛选价值。
局限性
- 本文为事后分析,未报告样本量、P值等具体数值,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The purpose of this paper is to evaluate patient characteristics and treatment outcomes in patients with nonradiographic axial spondyloarthritis (nr-axSpA) eligible for a clinical trial based on the 2009 established Assessment of SpondyloArthritis International Society (ASAS) magnetic resonance imaging (MRI)-sacroiliac joint (SIJ) definition for sacroiliitis (established definition [ED]) in comparison to the 2021 preliminary proposed data-driven definitions (proposed definitions [PD]) for inflammatory and structural lesions on MRI-SIJ. METHODS: COAST-X is a phase 3, multicentre, randomised, double-blind, placebo-controlled nr-axSpA study on ixekizumab (IXE) or placebo up to 52 weeks. In this post hoc analysis, baseline MRI-SIJ scans of IXE and placebo arms were independently categorised using the ED (bone marrow oedema [BME]) and PD (PD-BME; PD-erosion/fat lesions [FAT]/deep FAT; PD Total) cut-offs for MRI-SIJ lesions into groups fulfilling ED, PD, ED but not PD, and vice versa. Patient demographics, baseline characteristics, and clinical outcomes at week 16, including ASAS40 and Bath Ankylosing Spondylitis Disease Activity Index 50% improvement (BASDAI50) response, mean BASDAI change from baseline, Axial Spondyloarthritis Disease Activity Score (ASDAS) clinically important improvement, and attainment of different ASDAS disease states, were reported descriptively for each definition. RESULTS: Patient demographics and baseline disease characteristics were balanced between all ED or PD MRI-SIJ+ cut-off subgroups. Within each treatment arm, the respective clinical outcomes showed similar results across all ED or PD MRI-SIJ+ cut-off subgroups, whereas outcomes in subgroups fulfilling ED but not PD and vice versa were slightly lower compared with ED or PD MRI‑SIJ+ cut-off subgroups. CONCLUSIONS: Patients fulfilling ED or PD of a positive MRI-SIJ showed similar baseline characteristics and clinical outcomes at week 16. In this analysis, PD did not outperform ED in the identification of patients for a clinical trial in nr-axSpA.
引用
- Baraliakos X, Navarro-Compán V, Ramiro S, et al. Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trials. Ann Rheum Dis. 2026. PMID: 42350183. doi:10.1016/j.ard.2026.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。